Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Orilanolimab (Primary)
Indications Autoimmune haemolytic anaemia
Focus Therapeutic Use
Sponsors Alexion AstraZeneca Rare Disease

Most Recent Events

08 Jul 2020 This trial has been discontinued in Spain, as per European Clinical Trials Database record.
11 May 2020 Planned initiation date changed from 1 Feb 2020 to 1 Jul 2021.
11 May 2020 Planned End Date changed from 31 Dec 2021 to 30 Apr 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com